Blenrep

GSK's Blenrep is a BCMA-directed ADC for multiple myeloma that was later withdrawn in some markets due to safety concerns. Its experience highlights the need for improved selectivity. Valink's V-Gate platform is designed to enhance tumour-versus-healthy discrimination, potentially mitigating similar toxicity risks in future ADCs.